 CTLA-4 Antigen
"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
| Descriptor ID |
D060908
|
| MeSH Number(s) |
D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
|
| Concept/Terms |
CTLA-4 Antigen- CTLA-4 Antigen
- Antigen, CTLA-4
- CTLA 4 Antigen
- Antigens, CD152
- CD152 Antigens
- Cytotoxic T-Lymphocyte-Associated Antigen 4
- Cytotoxic T Lymphocyte Associated Antigen 4
- Cytotoxic T-Lymphocyte Antigen 4
- Cytotoxic T Lymphocyte Antigen 4
- CD152 Antigen
- Antigen, CD152
|
Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- CTLA-4 Antigen [D12.776.543.750.705.222.750]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CTLA-4 Antigen [D23.050.301.264.894.158]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CTLA-4 Antigen [D23.101.100.894.158]
Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".
This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 4 | 4 | | 2009 | 0 | 4 | 4 | | 2011 | 0 | 3 | 3 | | 2012 | 3 | 1 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 0 | 2 | | 2015 | 2 | 4 | 6 | | 2017 | 1 | 2 | 3 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 3 | 4 | | 2021 | 2 | 4 | 6 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 | | 2024 | 1 | 0 | 1 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.
-
Asby SC, Thompson LE, Goedken M, Lucia SM, Dominguez AT, Kar A, Pitts TM, Kiseljak-Vassiliades K, Lang J, Aleksunes LM, Joy MS. Pathological findings of immunotherapy-induced nephrotoxicity in a humanized immune system mouse model. Kidney Int. 2025 May; 107(5):930-934.
-
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabb? F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, J?nne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Vaddi PK, Osborne DG, Nicklawsky A, Williams NK, Menon DR, Smith D, Mayer J, Reid A, Domenico J, Nguyen GH, Robinson WA, Ziman M, Gao D, Zhai Z, Fujita M. CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients. Front Immunol. 2023; 14:1173035.
-
Sahin A, Kocyigit I, Aslan K, Eroglu E, Demiray A, Eken A. Elevated checkpoint inhibitor expression and Treg cell number in autosomal dominant polycystic kidney disease and their correlation with disease parameters and hypertension. Clin Exp Med. 2023 Nov; 23(7):3631-3640.
-
Johnson J, Goldner W, Abdallah D, Qiu F, Ganti AK, Kotwal A. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. J Natl Compr Canc Netw. 2023 02 24; 21(3):281-287.
-
Barra JM, Kozlovskaya V, Burnette KS, Banerjee RR, Fraker CA, Kharlampieva E, Tse HM. Localized cytotoxic T cell-associated antigen 4 and antioxidant islet encapsulation alters macrophage signaling and induces regulatory and anergic T cells to enhance allograft survival. Am J Transplant. 2023 04; 23(4):498-511.
-
Hamada K, Yoshimura K, Oshinomi K, Hirasawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsui H, Ishiguro T, Sambe T, Ishida H, Horiike A, Wada S, Iwamoto S, Uchida N, Ogawa Y, Kobayashi S, Tsunoda T. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. Medicine (Baltimore). 2022 Jan 14; 101(2):e28339.
-
Sun MM, Seleme N, Chen JJ, Zekeridou A, Sechi E, Walsh RD, Beebe JD, Sabbagh O, Mejico LJ, Gratton S, Skidd PM, Bellows DA, Falardeau J, Fraser CL, Cappelen-Smith C, Haines SR, Hassanzadeh B, Seay MD, Subramanian PS, Williams Z, Gordon LK. Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade. J Neuroophthalmol. 2021 12 01; 41(4):519-530.
-
Prakadan SM, Alvarez-Breckenridge CA, Markson SC, Kim AE, Klein RH, Nayyar N, Navia AW, Kuter BM, Kolb KE, Bihun I, Mora JL, Bertalan MS, Shaw B, White M, Kaplan A, Stocking JH, Wadsworth MH, Lee EQ, Chukwueke U, Wang N, Subramanian M, Rotem D, Cahill DP, Adalsteinsson VA, Miller JW, Sullivan RJ, Carter SL, Brastianos PK, Shalek AK. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat Commun. 2021 10 12; 12(1):5955.
-
Constant BD, Dutmer CM, Arnold MA, Hall C, Abbott JK, de Zoeten EF. Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 04; 20(4):e696-e702.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|